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Summary Paracoccus yeei was identified as the etiologic agent of peritonitis in an ambulatory
peritoneal dialysis patient. While the old biochemical identification kits are not able to identify
this species, the new colorimetric VITEK 2 GN card correctly identified this isolate in 7 hours. Its
identity was confirmed by sequencing of the 16S rRNA gene.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Peritonitis is a common problem in patients treated by
automated peritoneal dialysis (APD). The most common
causative organisms are usually those of the skin flora, such
as coagulase-negative staphylococci.1 This report concerns
the isolation and easy identification of Paracoccus yeei as
the unusual etiologic opportunistic agent of peritonitis in
an APD patient using the new colorimetric VITEK 2 GN card;
identification was confirmed by sequencing of the 16S rRNA
gene.* Corresponding author. Tel.: +33 03 20 44 54 80;
fax: +33 03 20 44 48 95.
E-mail address: fwallet@chru-lille.fr (F. Wallet).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.03.030Case report
A 25-year-old male patient was admitted to the nephrology
unit because of suspected APD peritonitis. The patient had
been followed in the APD ward for one year because of renal
failure due to a primitive IgA nephropathy. Although the
patient was apyretic on admission, he complained of abdom-
inal pain. The peritoneal catheter exit site was of normal
appearance. Microscopic examination of the fluid revealed
315  106 cells/l with 75% polymorphonuclear cells, 10%
lymphocytes, and 15% monocytes. Gram staining did not
reveal any microorganism. His white blood cell count was
5.0  109/l with 72% polymorphonuclear cells, and his C-
reactive protein level was 63 mg/l (normal <6 mg/l). Renal
function was altered with a creatinine level of 73 mg/l
(646 mmol/l). Primary antibiotic therapy was started with
intraperitoneal administration of piperacillin (2 g four timesPublished by Elsevier Ltd. All rights reserved.
e174 F. Wallet et al.daily) and cephalothin (500 mg four times daily), resulting in
rapid improvement. The outcome was uneventful.
A peritoneal fluid specimen was cultured for aerobic and
anaerobic organisms in solid and in broth medium. After two
days, the aerobic brain—heart medium grew a Gram-negative
coccobacillus in pure culture. After 18 hours of subculturing,
thebacteria grewonbloodagar andchocolate agar plates inan
aerobic and CO2 atmosphere at 35 8C. No growth was obtained
under anaerobic conditions. The culture was weaker in brom-
cresol purple agar (48 h). Gram staining of the culture con-
firmed the presence of small Gram-negative coccobacilli with
O-shaped morphology. This non-motile, non-spore forming
bacterium showed white—gray, small (1 mm), and smooth to
mucoid, non-hemolytic colonies after 24 h incubation. The
bacterium was catalase- and oxidase-positive.
Phenotypic identification performed with the VITEK 2 GN
(BioMe´rieux, Marcy l’Etoile, France) card identified Paracoc-
cus yeei (excellent identification, probability = 99%). This
bacterium is rarely identified in clinical samples, hence we
were prompted to sequence the 16S rRNA of this bacterium.
DNA sequencing of the 16S rRNA gene was performed using
the Microseq 500 16S rDNA bacterial sequencing kit (Applied
Biosystems, Foster City, CA, USA). The 418-bp fragment
obtained was compared with NCBI GenBank entries using
the BLAST algorithm (http://www.ncbi.nlm.nih.gov/BLAST)
and showed 98% identity with a sequence from P. yeei
(accession number AY014179).
As recommended by Janda and Sharon,2 the final identi-
fication of the bacterium was achieved by sequencing 1300—
1500 bp. An extraction of bacterial DNA from bacterial cells
was performed by heating (100 8C, 10 min). DNA was ampli-
fied using universal primers fD1 and rp2 as described by
Weisburg.3 The PCR product was purified by Nucleospin
Extract II kit (Macherey-Nagel, Hoerdt, France) and
sequenced on an automated DNA sequencer (310 ABI Prism,
PE Applied Biosystems, Foster City, CA, USA). The 1323 bp
obtained was compared with NCBI GenBank entries using the
BLAST algorithm and showed 99% identity with a sequence
from P. yeei (accession number AY014169). This result was
confirmed using bioinformatics bacterial identification ana-
lysis (http://pbil.univ-lyon1.fr/bibi) giving 99.7% identity
with a sequence from P. yeei (accession number AY014169).
As no interpretative criteria have been published by the
Clinical and Laboratory Standards Institute (CLSI) for this type
ofbacterium, susceptibility testing toantimicrobial agentswas
performed using the minimum inhibitory concentration (MIC)
dilution method.4 The results were as follows: ampicillin
0.064 mg/l, amoxicillin—clavulanate 0.064 mg/l, ticarcillin
0.25 mg/l, ticarcillin—clavulanate 0.25 mg/l, piperacillin
8 mg/l, piperacillin—tazobactam 8 mg/l, cephalothin 4 mg/
l, cefotaxime 1 mg/l, ceftazidime 4 mg/l, cefepime 2 mg/l,
aztreonam 32 mg/l, imipenem 0.125 mg/l, tobramycin
0.5 mg/l, amikacin 0.5 mg/l, gentamicin 0.5 mg/l, and cipro-
floxacin 1 mg/l.
Discussion
P. yeei was formerly classified as a eugonic oxidizer group 2
(EO-2) strain.5 This aerobic Gram-negative coccobacillus is
found naturally in soil and brines. Recently, thirteen North
American strains corresponding to clinical human case infec-tions have been described at posteriori as P. yeei, as mole-
cular techniques have allowed the establishment of this new
species.6 Only one strain was obtained from an elderly male
patient on dialysis suffering from peritonitis. In Europe,
Funke et al.7 described a patient with a positive blood culture
due to P. yeei. The same isolate was also found in dermato-
logic bullous lesions, indicating the probable route of entry of
the bacterium. In this case, Funke et al. described the
difficulties in identifying P. yeei correctly by conventional
biochemical methods; no commercial biochemical kit existed
to identify this species correctly. Here we have shown that
the VITEK 2 GN gallery performs a good, fast phenotypic
identification of P. yeei when molecular methods are not
available. Use of this type of phenotypic kit may prevent this
species from being underdiagnosed.
The raw MIC values obtained suggest that this strain of P.
yeei is susceptible to the b-lactams, especially aminopenicil-
lins and carbapenems. Nevertheless the MICs of the third-
generation cephalosporins showed higher values. This relative
susceptibility to these antibiotics is uncommon in an environ-
mental species. The intraperitoneal administration of the
antibiotics used may have led to higher concentrations at
the infected site, leading to the eradication of the bacterium.
In our report, the source of this microorganism and the
route of entry into the body were difficult to determine.
Detailed questioning of the patient revealed that he regularly
went horse riding and was not strict with his hygiene prac-
tices after sessions. This could explain the colonization of the
peritoneal catheter exit by P. yeei, which is found naturally in
soil and could have been transmitted by the hands. P. yeei
may be considered as an unusual opportunistic bacterium in
ambulatory dialysis.
Nucleotide sequence accession number: the 1323-bp
sequence of the Paracoccus yeei strain isolated in this report
has been submitted to GenBank under accession number
EU514523.
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